Solwers published a profit warning on Saturday 1 February, stating that Q4 2024 EBIT is close to ze...
Redeye has revised its near-term estimates and valuation following the Q4 report, which showed resil...
Redeye updates its estimates and valuation following Lifco releasing its Q4 2024 report.
Redeye's view is that Lagercrantz reported another strong quarter in a challenging market.
Redeye is happy to see surprisingly upbeat numbers from Ependion.
Redeye comments on today’s news that the European Commission has asked EMA’s CHMP to consider two ad...
Redeye publish a preview ahead of Northbaze's Q4 results, set to be released on Februaty 20.
Redeye comments on the news that IRLAB has presented positive top-line data from the phase I study i...
Sales 0% and adj. EBIT +13% vs. ABGSCe Operating cash flow SEK 98m, vs ABGSCe SEK 6m Minor positive ...
Redeye provides its initial take on Lifco’s Q4 2024 report, which featured a slight sales beat and m...
Redeye comments on WntResearch’s conditional reverse acquisition of OPSY AB.
Redeye retains its positive view on Lagercrantz following a Q3 report in-line with our estimates.
Redeye provides an initial comment on Addnode’s Q4 report, showing solid numbers in all three Divisi...
Apathy drug candidate completed Ph 1 in elderly adults Positive PK, safety and tolerability data con...
Redeye updates on Evolution following Q4-results which were in with our forecasts.
Redeye states that Enea showed solid sales growth while EBITDA margin were slightly below expectatio...
Redeye comments on further news from the all-important US market.
Diagonal Bio är ett bioteknikbolag som utvecklar och säljer en analysplattform för identifiering av ...
Sales -3%, adj. EBIT -2m vs. ABGSCe Temporary incoming delivery delays push cash flow into Q1 Optimi...
Vitrolife continues stabilise its growth rate and is approaching high single-digit growth.
